

### COMPANY ANNOUNCEMENT

The following is a company announcement issued by the Company, in terms of the rules of Prospects MTF, a market regulated as a multi-lateral trading facility and operated by the Malta Stock Exchange (“Prospects”).

---

#### **Basis of Acceptance - €17,000,000 6% Unsecured Bonds 2033**

##### *QUOTE*

The Company is pleased to announce that the offer of €17,000,000 6% Unsecured Bonds 2033 (the “**New Bonds**”) has been subscribed in full. In terms of the prospectus dated 5 December 2022 (the “**Prospectus**”), the New Bonds were allocated to Existing Pharmacare Prospects MTF Bondholders and Authorised Intermediaries.

The New Bonds are expected to be admitted to listing on the Official List of the Malta Stock Exchange on 3 February 2023 and trading is expected to commence on the 6 February 2023. The redemption of the 2018 Prospects MTF Bonds (as defined in the Prospectus) is expected to be on the 3 February 2023.

Interest on the New Bonds at the rate of 6% shall start accruing on the 3 February 2023. The Board of Directors would like to reiterate their appreciation to the Existing Pharmacare Prospects MTF Bondholders who subscribed to the New Bonds for their continued confidence in the Issuer over the years, the investing public and the participating Authorised Intermediaries for their support in this successful bond issue.

##### *UNQUOTE*

*By order of the Board*



Dr Katia Cachia  
**Company Secretary**

**REFERENCE PHC59**

27<sup>th</sup> January 2023